RxDoctor Payments Data

Leslie Tolliver, PA

Surgical · Anchorage, AKNPI 1679920565

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 40.4% of the total. Reporting peaked in 2022 at $84 and has fallen 71.2% since, to $24 in 2025. That places this record below the midpoint for surgical clinicians in AK, where the typical reported total is $523.

$231in general payments, 2019–2025

Across 14 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$93
  • Pfizer$51
  • AbbVie$19
  • Novo Nordisk$17
  • Lilly USA, LLC$14
  • Eisai Inc.$13
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$231100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$231 in reported general payments places this provider in the 30th percentile of 31 surgical providers in Alaska.

See all surgical providers in Alaska

Medicare billing

Part B allowed, 2024
$121,404
Medicare patients
435
Services billed
2,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$49,553
MounjaroTirzepatide14$16,528
PaxlovidNirmatrelvir/Ritonavir23$5,674
SynthroidLevothyroxine Sodium14$1,351
Atorvastatin Calcium82$1,195
Montelukast Sodium20$807
Levothyroxine Sodium50$807
Losartan Potassium43$637
Trazodone Hcl33$574
Duloxetine Hcl19$546
Ipratropium Bromide12$543
Albuterol Sulfate HfaAlbuterol Sulfate23$518
Pantoprazole Sodium19$489
Metoprolol Succinate27$436
Rosuvastatin Calcium24$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$49,55334 claims
Lilly USA, LLCMounjaro$14$16,52814 claims
PfizerPaxlovid$51$5,67423 claims
AbbVieSynthroid$19$1,35114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 31 surgical providers in Alaska.

Other surgical in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →